Dominic Cummings mocks Rishi Sunak and Matt Hancock on WhatsApp leaks

 mocked and Matt Hancock today after leaked WhatsApps revealed brutal sniping at him over Covid. The maverick former No10 chief added ‘nightmare psychotherapist’ to his Twitter bio as he ridiculed the backbiting.  The latest tranche of Mr Hancock’s messages disclosed to the Telegraph give an extraordinary insight into the ongoing feud between Mr Cummings and…

Read More

Sherlock Bio to buy UK firm in quest for CRISPR-based handheld…

Feb 1 (Reuters) — Privately-held Sherlock Biosciences said on Wednesday it has acquired UK-based Sense Biodetection to speed up the launch of handheld diagnostic tests that use the breakthrough CRISPR gene editing technology. Sherlock raised $80 million nearly a year ago for link bio development of diagnostics based on the CRISPR tool, which is designed…

Read More

POLL-Brazil's central bank to keep wary stance against govt flak

<p website poll data By Gabriel Burin BUENOS AIRES, Jan 27 (Reuters) — Brazil’s central bank will keep a wary stance next week against strong criticism from recently elected President Luiz Inacio Lula da Silva, maintaining the Selic benchmark rate at current high levels, a Reuters poll suggests. Investors are focusing on how hawkish the…

Read More

POLL-S.Africa's budget deficit to fall slower than government hopes

<p website GDP forecasts * <p website Repo rate predictions By Vuyani Ndaba JOHANNESBURG, Feb 17 (Reuters) — Mining tax receipts will keep topping up South Africa’s public purse, but crimped growth from erratic power generation and financial support to struggling state-owned enterprises will mean more wide budget deficits to come, a Reuters poll found.…

Read More

Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal

By Ludwig Burger and Dina Kartit March 13 (Reuters) — France’s Sanofi SA on Monday agreed to acquire Provention Bio Inc for $2.9 billion to bolster its work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks. The deal builds on an existing co-promotion agreement between the two companies,…

Read More

Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal

By Ludwig Burger and Dina Kartit March 13 (Reuters) — France’s Sanofi SA on Monday agreed to acquire Provention Bio Inc for $2.9 billion to bolster its work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks. The deal builds on an existing co-promotion agreement between the two companies,…

Read More